Author Archives: Lu Rahman

#Clinical trials #Immunology / Virology & Vaccines #Therapeutics

Peanut allergy biomarker study may lead to novel peanut vaccine candidate

Allergy Therapeutics, the specialty pharmaceutical company specialising in allergy vaccines, has announced that an ex-vivo biomarker study of blood samples from peanut allergy patients has begun at Imperial College London. The study aims to evaluate the group’s novel virus like particle (VLP) based peanut allergy vaccine candidate, to confirm its… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Biologics #Drug discovery #Pharmaceuticals

Is the pharmaceutical industry ready to listen directly to patients?

Dr Elizabeth Fairley, COO and co-founder of social intelligence company Talking Medicines, explains how technology has shaped the drug landscape and why actually listening to patients might be the breakthrough the industry needs. There are more drugs on the market today than ever before and the drug pipeline is massively… Read More

#Editor's Choice #News #Opinion

#Covid-19 #Immunology / Virology & Vaccines

WHO issues emergency use validation for COVID-19 vaccine

The World Health Organization (WHO) has listed the COVID-19 mRNA vaccine for emergency use, making the Pfizer/BioNTech vaccine the first to receive emergency validation from WHO since the outbreak began a year ago. The WHO’s Emergency Use Listing (EUL) opens the door for countries to expedite their own regulatory approval… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines

“A moment to celebrate British innovation”: Oxford AstraZeneca vaccine gets go-ahead

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has provided authorisation for emergency supply of the Oxford University AstraZeneca COVID-19 vaccine for the active immunisation of individuals 18 years or older. The authorisation recommends two doses administered with an interval of between four and 12 weeks. This regimen was shown… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

“A great day for British science”: MHRA approves Oxford COVID-19 vaccine

The UK government has accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK. The Joint Committee on Vaccination and Immunisation (JCVI) will also publish its latest advice for the priority groups to receive… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Antibody #Assay development optimisation & technology

LSBIO acquires Absolute Antibody

LSBio, a provider of antibodies and life science research reagents, has acquired UK-based Absolute Antibody, its sister company Kerafast. LSBio provides IHC-validated reagent antibodies and services to the global community of academic, pharmaceutical and biotech researchers. The company has built a catalogue of more than 750,000 reagent antibodies, assay kits,… Read More

#News #Trending News

#Genetics #Immune cells

New 3D maps reveal inner workings of immune cell gene expression

The COVID-19 pandemic has highlighted how our small genetic differences can have a tremendous effect on how our bodies respond to disease. “The difference is within us,” said Vivek Chandra, an instructor at La Jolla Institute for Immunology (LJI). “We can get infected by the same bacteria or viruses, but… Read More

#News

#Drug development

Funding boost for tech that translates novel plant molecules into medicines

Enveda Biosciences’ $4.9 million seed round of funding will enable the company to grow its medicinal plant dataset, enhance its technologies and algorithms to accelerate natural product drug discovery and advance its lead asset for liver fibrosis through preclinical development. The funding was led by True Ventures, with participation from… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines

COVID-19 vaccine: “That is how our country will begin to move forward,” says Fauci

The FDA has issued an Emergency Use Authorization (EUA) to Moderna, for its COVID-19 vaccine, which was co-developed with scientists at the NIH National Institute of Allergy and Infectious Diseases (NIAID) and Moderna. This partnership has enabled NIH and Moderna to develop a COVID-19 vaccine within a year that will… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Drug development #Drug discovery #Therapeutics

Small molecule therapeutics: solubility with permeability to achieve better bioavailability

Technologies have been honed to overcome many of the challenges of administering BCS class II and IV small molecule therapeutics says John S. Vrettos, Senior Principal Scientist & Head of Formulation Development, Enteris BioPharma Small molecule drugs have traditionally dominated the treatment of human disease given their diverse mechanisms of… Read More

#Exclusive Content

#Antibody #Covid-19 #Immunology / Virology & Vaccines #T-Cells

Oxford vaccine stimulates broad antibody and T cell functions

Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing Phase III trials, and how ChAdOx1 nCov-19 is induces broad antibody and T cell functions. These findings… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Biologics #Drug development #Drug discovery #Oncology #Therapeutics

International consortium awarded grant for first-in-class metastatic cancer treatment

ONA Therapeutics, Absolute Antibody and RIC – three leading European companies in the biotech landscape – have been awarded a Eurostars grant for a two-year project that will develop a proprietary biological drug with a unique mode of action for the treatment of various types of metastatic cancers. Taking the… Read More

#Cancer Research #News